News

On July 30, the National Medical Products Administration (NMPA) officially approved the marketing of HICARA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who have received two or more lines of systemic therapy. This includes diffuse large B-cell ...Read more »

Recently, a patient with advanced pancreatic cancer who had failed multiple prior treatment lines achieved sustained tumor shrinkage after receiving KD-496 CAR-T cell therapy, with confirmed remission maintained at 180 days post-treatment. At present, there are still many clinical trials of new a...Read more »

On July 16, the top-tier international journal Nature Medicine published research data on SHR-A1904, an antibody-drug conjugate (ADC) targeting claudin 18.2 (CLDN18.2), for the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC). The researchers conducted a first-in...Read more »

July 17, 2025 – Innovent Biologics announced that Nature Medicine has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Publication in this leading international a...Read more »

On July 17, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that the marketing application for Trastuzumab Deruxtecan (Enhertu®) for the second-line treatment of gastric cancer has been officially accepted by the NMPA. This application is inte...Read more »

Recently，Ascentage Pharma  announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...Read more »

Recently，GenFleet Therapeutics announced the Pharmaceutical Administration Bureau (ISAF) of China’s Macau Special Administrative Region has approved Dupert®（fulzerasib, GFH925/IBI351）for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring KRAS G12C mutati...Read more »

On June 30, Avistone’s independently developed MET inhibitor Vebreltinib received conditional approval from the National Medical Products Administration (NMPA) of China for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET amplifi...Read more »

On June 30, 2025，HUTCHMED announces that the New Drug Application (NDA) for the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) has been granted approval by the China National Medical Products Administration (NMPA) for the treatment of patients with locally advanced or metastati...Read more »

On June 30, the official website of the National Medical Products Administration (NMPA) announced that Anlotinib, a Class 1 new drug developed by Chia Tai Tianqing, has received approval for a new indication in China: combination therapy with chemotherapy for the first-line treatment of patients ...Read more »

On June 26, 2025, CARsgen announces that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for the treatment of Claudi...Read more »

On June 19, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Livzon Pharmaceutical’s LM-108 injection has been proposed for inclusion in the breakthrough therapy designation. The combination of Kefeqibai monoclonal antibody injection (LM-1...Read more »